Concordia Healthcare (CHEHF) 47.7000 $CHEHF
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.46 (+0.01), TRIL: 13.25 (-0.75)
Concordia Healthcare Corp. Provides Corporate Update
CNW Group - Thu Feb 12, 4:55PM CST
Concordia Healthcare Corp., ("Concordia"
(TSX: CXR) (OTCQX: CHEHF), today provided a corporate update on various matters, including its Phase 3 clinical trial to treat a rare form of bile duct cancer.
CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. Announces Change to Board of Directors
CNW Group - Mon Dec 22, 6:00AM CST
Concordia Healthcare Corp. ("Concordia" or the "Company" (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that Paul Manning has resigned from the Board of Directors of the Company, effective January 2, 2015.
CXR.TO: 59.50 (+0.50)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Concordia Healthcare Corp. Provides Clinical Trial and Corporate Update
PR Newswire - Fri Nov 28, 6:00AM CST
Concordia Healthcare Corp., ("Concordia" (TSX: CXR) (OTCQX: CHEHF), announced today a clinical trial and corporate update, including the status of patient enrollment in its Phase 3 clinical trial to treat a rare form of bile duct cancer, and the entering into of an exclusive trademark license and product distribution agreement for China and other Asian territories with Union Med. Limited.
CXR.TO: 59.50 (+0.50)
EDC Announces USD 22.5 M in Recently Completed Concordia Healthcare Corp. Financings
Marketwire Canada - Tue Nov 18, 11:32PM CST
Export Development Canada (EDC) today announced it participated in two recent financings for Oakville-based Concordia Healthcare Corp. ("Concordia" or "the Company" (TSX: CXR) (OTCQX: CHEHF). Concordia deployed the EDC financing to help acquire pharmaceutical products for distribution in the United States.
CXR.TO: 59.50 (+0.50)
Concordia Healthcare Announces Third Quarter Results - Revenue up 147%, EBITDA up 80% Over Comparative Period
CNW Group - Thu Nov 13, 5:17PM CST
Concordia Healthcare Corp. ("Concordia" or the "Company" (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014.
CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. to host third quarter 2014 results conference call
CNW Group - Thu Oct 23, 1:00PM CDT
Concordia Healthcare Corp. ("Concordia" or "the Company" (TSX: CXR) (OTCQX: CHEHF), today announced it will release its third quarter 2014 financial results after market close on Thursday, November 13, 2014. The Company will subsequently hold a conference call on Friday, November 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, Mr. Leith Tessy, Chief Financial Officer, and Mr. Wayne Kreppner, Chief Operating Officer. A question-and-answer session will follow the corporate update.
CXR.TO: 59.50 (+0.50)
Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announces European site initiation of Phase 3 bile duct cancer trial using photodynamic therapy with PHOTOFRIN®
PR Newswire - Tue Oct 07, 6:00AM CDT
University of Mannheim Medical Center is first site opened
CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. Announces Completion of Zonegran® Acquisition
CNW Group - Tue Sep 30, 4:00PM CDT
Concordia Healthcare Corp. ("Concordia" or the "Company" (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc. ("CPI" , has completed the previously announced acquisition of Zonegran® (zonisamide) for commercialization and sale in the United States, including Puerto Rico.
CXR.TO: 59.50 (+0.50)
Eisai Sells U.S. Rights to Zonegran® (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
PR Newswire - Wed Sep 03, 6:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia" , a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran. As part of the deal terms, Eisai will receive full payment from Concordia upon closing. In addition, Eisai and Concordia are expected to enter into a supply agreement under which Eisai will serve as Concordia's supplier of Zonegran for the U.S. and Puerto Rican markets.
Concordia Healthcare Announces Agreement to Acquire Zonegran® in the United States and Puerto Rico
CNW Group - Wed Sep 03, 6:00AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc., has entered into a definitive agreement with Eisai Inc. ("Eisai" to acquire Zonegran® for commercialization and sale in the United States, including Puerto Rico.
CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. enters into collaboration agreement with Orphan Canada
PR Newswire - Tue Sep 02, 6:00AM CDT
Concordia Healthcare Corp. ("Concordia" (TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc. ("Pinnacle" , a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® (porfimer sodium) with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada. Under the agreement, Pinnacle and Orphan Canada will partner to support the continued supply of Photodynamic Therapy (PDT) using PHOTOFRIN in Canada.
CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. Announces Financial and Operational Results for its Second Quarter, Ended June 30, 2014
CNW Group - Wed Aug 13, 4:00PM CDT
Concordia Healthcare Corp. ("Concordia" or the "Company" (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and six months ended June 30, 2014.
CXR.TO: 59.50 (+0.50)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.46 (+0.01), TRIL: 13.25 (-0.75)
Concordia Healthcare Corp. Provides Corporate Update
CNW Group - Thu Feb 12, 4:55PM CST
Concordia Healthcare Corp., ("Concordia"
(TSX: CXR) (OTCQX: CHEHF), today provided a corporate update on various matters, including its Phase 3 clinical trial to treat a rare form of bile duct cancer. CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. Announces Change to Board of Directors
CNW Group - Mon Dec 22, 6:00AM CST
Concordia Healthcare Corp. ("Concordia" or the "Company"
(TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that Paul Manning has resigned from the Board of Directors of the Company, effective January 2, 2015. CXR.TO: 59.50 (+0.50)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Concordia Healthcare Corp. Provides Clinical Trial and Corporate Update
PR Newswire - Fri Nov 28, 6:00AM CST
Concordia Healthcare Corp., ("Concordia"
(TSX: CXR) (OTCQX: CHEHF), announced today a clinical trial and corporate update, including the status of patient enrollment in its Phase 3 clinical trial to treat a rare form of bile duct cancer, and the entering into of an exclusive trademark license and product distribution agreement for China and other Asian territories with Union Med. Limited. CXR.TO: 59.50 (+0.50)
EDC Announces USD 22.5 M in Recently Completed Concordia Healthcare Corp. Financings
Marketwire Canada - Tue Nov 18, 11:32PM CST
Export Development Canada (EDC) today announced it participated in two recent financings for Oakville-based Concordia Healthcare Corp. ("Concordia" or "the Company"
(TSX: CXR) (OTCQX: CHEHF). Concordia deployed the EDC financing to help acquire pharmaceutical products for distribution in the United States. CXR.TO: 59.50 (+0.50)
Concordia Healthcare Announces Third Quarter Results - Revenue up 147%, EBITDA up 80% Over Comparative Period
CNW Group - Thu Nov 13, 5:17PM CST
Concordia Healthcare Corp. ("Concordia" or the "Company"
(TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014. CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. to host third quarter 2014 results conference call
CNW Group - Thu Oct 23, 1:00PM CDT
Concordia Healthcare Corp. ("Concordia" or "the Company"
(TSX: CXR) (OTCQX: CHEHF), today announced it will release its third quarter 2014 financial results after market close on Thursday, November 13, 2014. The Company will subsequently hold a conference call on Friday, November 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, Mr. Leith Tessy, Chief Financial Officer, and Mr. Wayne Kreppner, Chief Operating Officer. A question-and-answer session will follow the corporate update. CXR.TO: 59.50 (+0.50)
Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announces European site initiation of Phase 3 bile duct cancer trial using photodynamic therapy with PHOTOFRIN®
PR Newswire - Tue Oct 07, 6:00AM CDT
University of Mannheim Medical Center is first site opened
CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. Announces Completion of Zonegran® Acquisition
CNW Group - Tue Sep 30, 4:00PM CDT
Concordia Healthcare Corp. ("Concordia" or the "Company"
(TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc. ("CPI" , has completed the previously announced acquisition of Zonegran® (zonisamide) for commercialization and sale in the United States, including Puerto Rico. CXR.TO: 59.50 (+0.50)
Eisai Sells U.S. Rights to Zonegran® (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
PR Newswire - Wed Sep 03, 6:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"
, a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran. As part of the deal terms, Eisai will receive full payment from Concordia upon closing. In addition, Eisai and Concordia are expected to enter into a supply agreement under which Eisai will serve as Concordia's supplier of Zonegran for the U.S. and Puerto Rican markets. Concordia Healthcare Announces Agreement to Acquire Zonegran® in the United States and Puerto Rico
CNW Group - Wed Sep 03, 6:00AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc., has entered into a definitive agreement with Eisai Inc. ("Eisai"
to acquire Zonegran® for commercialization and sale in the United States, including Puerto Rico. CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. enters into collaboration agreement with Orphan Canada
PR Newswire - Tue Sep 02, 6:00AM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc. ("Pinnacle" , a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® (porfimer sodium) with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada. Under the agreement, Pinnacle and Orphan Canada will partner to support the continued supply of Photodynamic Therapy (PDT) using PHOTOFRIN in Canada. CXR.TO: 59.50 (+0.50)
Concordia Healthcare Corp. Announces Financial and Operational Results for its Second Quarter, Ended June 30, 2014
CNW Group - Wed Aug 13, 4:00PM CDT
Concordia Healthcare Corp. ("Concordia" or the "Company"
(TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and six months ended June 30, 2014. CXR.TO: 59.50 (+0.50)
